Skip to main content
SpringerLink
Log in

Investigations After Adjuvant Therapy

  • Chapter
  • First Online:
Book cover Adjuvant Therapy for Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 151))

  • 1194 Accesses

More than 2 million women in the US alone are living with a history of breast cancer. Most women in whom breast cancer is diagnosed do not die of the disease: of the 180,000 women who receive a diagnosis of invasive breast cancer in the US every year, more than 80% can expect to survive for at least 5 years [1].

“As the morning progresses the hospital waiting area fills up with anxious, mostly gray haired women. They have been treated for breast cancer in the past and are attending for “routine” follow up. For those who are apparently free of disease, what is the purpose of follow up, how often should it be done, and by whom, and what investigations, if any, should be performed routinely?”

[Dewar J. Follow up in breast cancer: A suitable case for reappraisal. BMJ. 1995;310:685.]

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. NEJM. 2000;343(15):1086–94

    Article  PubMed  CAS  Google Scholar 

  2. Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M. Routine follow up of breast cancer in primary care: Randomised trial. BMJ. Sep 1996;14;313(7058):665–9

    Article  Google Scholar 

  3. Tomiak E, Piccart M. Routine follow-up of patients after primary therapy for early breast cancer: Changing concepts and challenges for the future. Ann Oncol. 1993;4:199–204

    PubMed  CAS  Google Scholar 

  4. Loprinzi CL. It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol. 1994;12(5):881–3.

    PubMed  CAS  Google Scholar 

  5. Jiwa M, Thompson J, Coleman R, Reed M. Breast cancer follow-up: Could primary care be the right venue? Curr Med Res Opin. 2006;22(4):625–30.

    Article  PubMed  Google Scholar 

  6. Mille D, Roy T, Carrère M, Ray I, Ferdjaoui N, Späth H, Chauvin F, Philip T. Economic impact of harmonizing medical practices: Compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol, April 2000;18(8):1718–24.

    PubMed  CAS  Google Scholar 

  7. de Bock GH, Bonnema J, van der Hage J, et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-analysis and systematic review. J Clin Oncol. 2004;22:4010–8.

    Article  PubMed  Google Scholar 

  8. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Oxford, United Kingdom, Cochrane Library, CD001768, 1, 2005.

    Google Scholar 

  9. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnositic follow up after treatment of primary breast cancer. JAMA. 1994;271:1593–7.

    Article  PubMed  CAS  Google Scholar 

  10. Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P, for the National Research Council Project on Breast Cancer Follow-up. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. JAMA. 1999;281(17):1586.

    Article  PubMed  CAS  Google Scholar 

  11. GIVIO Investigators. Impact of follow up testing on survival and health-related quality of life in breast cancer patients. JAMA. 1994;271:1587–92.

    Article  Google Scholar 

  12. Liberati A. The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Ann Oncol. 1995;6(Suppl 2):41–6.

    PubMed  Google Scholar 

  13. Gulliford T, Opomu M, Wilson E, et al. Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study. BMJ. 1997;314:174–7.

    Article  PubMed  CAS  Google Scholar 

  14. American Society of Clinical Oncology: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer: Adopted on November 7, 1997, by the American Society of Clinical Oncology. J Clin Oncol. 1998;16:793–5.

    Google Scholar 

  15. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–9.

    Google Scholar 

  16. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. J Clin Oncol. 24(31):1–7.

    Article  Google Scholar 

  17. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 and BRCA2 mutations. JAMA. 2000;283:617–24.

    Article  PubMed  CAS  Google Scholar 

  18. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84.

    Article  PubMed  CAS  Google Scholar 

  19. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer. 1998;34:2000–9.

    Article  PubMed  CAS  Google Scholar 

  20. Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidemiol. 1992;136:937–48.

    PubMed  CAS  Google Scholar 

  21. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781–5.

    Article  PubMed  Google Scholar 

  22. Grunfeld E, Noorani H, McGahan L, et al. Surveillance mammography after treatment of primary breast cancer: A systematic review. Breast. 2002;11:228–35.

    Article  PubMed  CAS  Google Scholar 

  23. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone Imaging in Metastatic Breast Cancer. J Clin Oncol. 2004;22:2942–53.

    Article  PubMed  Google Scholar 

  24. Drotman MB, Machnicki SC, Schwartz LH, et al. Breast cancer: Assessing the use of routine pelvic CT in patient evaluation. Am J Roentgenol. 2001;176:1433–6.

    CAS  Google Scholar 

  25. Hurria A, Leung D, Trainor K, et al. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag. 2003;12:13–5.

    PubMed  Google Scholar 

  26. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43:325–9.

    PubMed  Google Scholar 

  27. Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129:147–53.

    PubMed  Google Scholar 

  28. Isasi CR, Moadel RM, Blaufox MD. A metaanalysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105–12.

    Article  PubMed  CAS  Google Scholar 

  29. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.

    Article  PubMed  Google Scholar 

  30. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicenter cohort study (MARIBS). Lancet. 2005;365:1769–78.

    Article  PubMed  CAS  Google Scholar 

  31. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem. 2006;52(3):345–51.

    Article  PubMed  CAS  Google Scholar 

  32. Hietanen P. Response to follow-up of breast cancer. Strahlentherapie. 1985;161:678–80.

    PubMed  CAS  Google Scholar 

  33. Muss HB, Tell GS, Case LD, Robertson P, Atwell BM. Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol. 1991;14:55–9.

    Article  PubMed  CAS  Google Scholar 

  34. Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests? Classic Papers, suppl to J Clin Oncol. 2003, 21(9):108–11.

    Article  Google Scholar 

  35. Warmuth MA, Bowen G, Prosnitz L, et al. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey. Cancer. 1998;83:1362–8.

    Google Scholar 

  36. Johnson CH, van Heerden JA, Donohue JH, Martin JK Jr, Jackson IT, Ilstrup DM. Oncological aspects of immediate breast reconstruction following mastectomy for malignancy. Arch Surg 1989;124:819–23.

    Article  PubMed  CAS  Google Scholar 

  37. Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg. 1994;93:1191–204.

    Article  PubMed  CAS  Google Scholar 

  38. Petrek JA, Lerner R. Lymphedema. Harris JR, Lippman ME, Morrow M, Osborne K, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:1033–40.

    Google Scholar 

  39. Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.

    Article  PubMed  CAS  Google Scholar 

  40. Pezner RD, Patterson MP, Hill LR, et al. Arm lymphedema in patients treated conservatively for breast cancer: Relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079–83.

    Article  PubMed  CAS  Google Scholar 

  41. Bertelli G, Venturini M, Forno G, Macchiavello F, Dini D. Conservative treatment of postmastectomy lymphedema: a controlled, randomized trial. Ann Oncol. 1991;2:575–8.

    PubMed  CAS  Google Scholar 

  42. Rockson SG. Precipitating factors in lymphedema: Myths and realities. Cancer. 1998;83:2814–6.

    Article  PubMed  CAS  Google Scholar 

  43. Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209–16.

    PubMed  CAS  Google Scholar 

  44. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. Lippman ME, ed. National Institutes of Health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI monographs. No. 1. Washington, D.C.: Government Printing Office, 1986:105-9. (NIH publication no. 86–2860.)

    Google Scholar 

  45. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–501.

    PubMed  CAS  Google Scholar 

  46. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.

    PubMed  CAS  Google Scholar 

  47. Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G. Second malignancies following CMF-based adjuvant chemotherapy in respectable breast cancer. Ann Oncol. 1994;5:803–8.

    PubMed  CAS  Google Scholar 

  48. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722–30.

    PubMed  CAS  Google Scholar 

  49. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001;30:67–71.

    Article  PubMed  Google Scholar 

  50. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.

    PubMed  CAS  Google Scholar 

  51. Davidson NE. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr. 1994;16:95–99.

    PubMed  Google Scholar 

  52. Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (ACT) in early stage breast cancer. Breast Cancer Res Treat. 2000;64:61(abstr 224).

    Google Scholar 

  53. Minton SE, Munster PN. Chemotherapy induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9:466–72.

    PubMed  Google Scholar 

  54. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18.

    Article  PubMed  CAS  Google Scholar 

  55. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–7.

    Article  PubMed  CAS  Google Scholar 

  56. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–69.

    Google Scholar 

  57. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17:1488–92.

    PubMed  CAS  Google Scholar 

  58. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.

    PubMed  CAS  Google Scholar 

  59. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat. 1998;48:81–5.

    Article  PubMed  CAS  Google Scholar 

  60. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol. 1992;45:118–28.

    Article  PubMed  CAS  Google Scholar 

  61. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91:1654–62.

    Article  PubMed  CAS  Google Scholar 

  62. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.

    Article  PubMed  CAS  Google Scholar 

  63. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.

    Google Scholar 

  64. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341–7.

    PubMed  CAS  Google Scholar 

  65. Powles TJ, McCloskey E, Paterson AHG, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704–8.

    Article  PubMed  CAS  Google Scholar 

  66. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736–46.

    Article  PubMed  CAS  Google Scholar 

  67. Nixon AJ, Manola J, Gelman R, et al. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol. 1998;16:1374–9.

    PubMed  CAS  Google Scholar 

  68. Hojris, I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet. 1999;354:1425–30.

    Article  PubMed  CAS  Google Scholar 

  69. Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol. 1998;16:2625–31 (Erratum, J Clin Oncol. 1999;17:740.

    PubMed  CAS  Google Scholar 

  70. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018–24.

    PubMed  CAS  Google Scholar 

  71. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node negative breast cancer. J Natl Cancer Inst Monogr. 1992, 11, 117–20.

    PubMed  Google Scholar 

  72. Nordenskjöld B, Rosell J, Rutqvist LE, et al. The Swedish Breast Cancer Group trail of two versus five years of adjuvant tamoxifen: reduced coronary heart disease death rate in the five years group. Ann Oncol. 2004, 15(Suppl. 3), iii54–iii55 (Abstract 2060).

    Article  Google Scholar 

  73. Grunfeld E, Mant D, Vessey MP, Yudkin P. Evaluating primary care follow-up of breast cancer: Methods and preliminary results of three studies. Ann Oncol. 1995;6(Suppl 2):47–52.

    PubMed  Google Scholar 

  74. Grunfeld E, Fitzpatrick R, Mant D, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: Results from a randomized controlled trial. Br J Gen Pract. 1999 Sep;49(446):705–10.

    PubMed  CAS  Google Scholar 

  75. Grunfeld E, Gray A, Mant D, et al. Follow-up of breast cancer in primary care vs specialist care: Results of an economic evaluation. Br J Cancer. 1999;79:1227–33.

    Article  PubMed  CAS  Google Scholar 

  76. Worster A, Bass MJ, Wood ML. Willingness to follow breast cancer. Survey of family physicians. Can Fam Physician. 1996;42:263–8.

    PubMed  CAS  Google Scholar 

  77. Goodwin PJ. Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Evid Based Med. May 1,2000; 5(3):89.

    Article  Google Scholar 

  78. Rainsbury D. Routine follow up of breast cancer in primary care. BMJ. 1996 313:1547.

    Article  PubMed  CAS  Google Scholar 

  79. Dixon JM, Norman B. Most recurrences after breast conservation are detected by regular hospital visits. BMJ. 1996;313:1548.

    Article  PubMed  CAS  Google Scholar 

  80. Grunfeld E, Levine MN, Julian JA, et al. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician versus Specialist Care. J Clin Oncol. 2006;24(6):848–55.

    Article  PubMed  Google Scholar 

  81. Newell S, Sanson-Fisher RW, Girgis A, et al. How well do medical oncologists’ perceptions reflect their patients’ reported physical and psychosocial problems? Data from a survey of five oncologists. Cancer. 1998; 83:1640–51

    Article  PubMed  CAS  Google Scholar 

  82. Khatcheressian JL, Smith TJ. Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol. 20 February 2006;24(6):835–7.

    Article  PubMed  Google Scholar 

  83. Early Breast Cancer Trialists’ Collaborative Group: Effects of Chemotherapy and Hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  84. Institute of Medicine and National Research Council, Committee on Cancer Survivorship: Improving care and quality of life, National Cancer Policy Board. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press, 2005.

    Google Scholar 

  85. Dewar J. Follow up in breast cancer: A suitable case for reappraisal. BMJ. 1995;310:685.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, European Institute of Oncology, Milan, Italy

    Silvia Dellapasqua (Assistant, Medical Senology Research Unit)

Authors
  1. Silvia Dellapasqua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Dellapasqua .

Editor information

Editors and Affiliations

  1. Inselspital, Univ. Bern, Bern, 3010, Switzerland

    Monica Castiglione

  2. Inst. Jules Bordet, Universite Libre Bruxelles, Bd. de Waterloo 125, Bruxelles, 1000, Belgium

    Martine J. Piccart

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Dellapasqua, S. (2009). Investigations After Adjuvant Therapy. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75115-3_21

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-75114-6

  • Online ISBN: 978-0-387-75115-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation